StockDuty
Jun 30, 2026 06:18 PM ET
Catalyst
FDA/Bio
UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA
Second CRL for hyperphosphatemia treatment OLC triggers sharp Unicycive stock decline.
What changed
UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA
Why it matters
Second CRL for hyperphosphatemia treatment OLC triggers sharp Unicycive stock decline.
Sources
seekingalpha
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →
IONIS PHARMACEUTICALS, INC. (IONS) DISCUSSES FDA APPROVAL OF TRYNGOLZA FOR SEVERE HYPERTRIGLYCERIDEMIA AND ACUTE PANCREA →
LG CHEM SECURES FDA CLEARANCE FOR TP53-TARGETING CANCER CANDIDATE - KOREAHERALD →